Showing 3791-3800 of 6808 results for "".
- Vial to Host Advisory Boardhttps://practicaldermatology.com/news/vial-to-host-advisory-board/2461038/Vial is hosting an Advisory Board with leading research sites to discuss the challenges in clinical research. Launched in conjunction with the 2022 Winter Clinical Dermatology conference, the meeting will focus on improving speed and quality of trials in dermatology. The Vial executive
- Scleroderma Research Foundation Announces $1.5M Matching Gift in Honor of Bob Sagethttps://practicaldermatology.com/news/scleroderma-research-foundation-announces-15m-matching-gift-in-honor-of-bob-saget/2461035/The Scleroderma Research Foundation (SRF) announced a $1.5M matching gift in honor of Bob Saget, a SRF
- BTL Introduces EMFACE Technologyhttps://practicaldermatology.com/news/btl-introduces-emface-technology/2461033/Described as the result of many years of institutional knowledge of the simultaneous emission of radio frequency and electromagnetic energies, EMFACE™ is the newest innovation from BTL. It utilizes a patented technology of muscle contraction and skin tissue heating. &quo
- Drug Combination Boosts Progression-free Survival in Advanced Melanomahttps://practicaldermatology.com/news/drug-combination-boosts-progression-free-survival-in-advanced-melanoma/2461027/Combining relatlimab and nivolumab (Opdivo) may double progression-free survival in patients with advanced melanoma, according to a new study in the New England Journal of Medicine. Relatlimab, which blocks
- FDA Accepts Arcutis Biotherapeutics’ NDA for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasishttps://practicaldermatology.com/news/fda-accepts-arcutis-biotherapeutics-nda-for-roflumilast-cream-for-adults-and-adolescents-with-plaque-psoriasis/2461018/The FDA accepted Arcutis Biotherapeutics’ new drug application (NDA) for roflumilast cream for the treatment of psoriasis in adults and adolescents. The FDA assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2022. “With the FDA c
- FDA Accepts NDA for Boehringer Ingelheim’s Spesolimab for GPPhttps://practicaldermatology.com/news/fda-accepts-nda-for-boehringer-ingelheims-spesolimab-for-gpp/2461010/FDA has accepted a Biologics License Application (BLA) and granted Priority Review for Boehringer Ingelheim’s spesolimab for the treatment of generalized pustular psoriasis (GPP) flares. The FDA has granted spesolimab Orphan Drug Designation for the treatment of GPP, and Bre
- BTL Launches Scholarship Program with Professional Basketball Player Andre Drummondhttps://practicaldermatology.com/news/btl-launches-scholarship-program-with-professional-basketball-player-andre-drummond/2460991/The BTL SCHOLAR DRAFT will grant five student athletes $15,000 each toward their college tuition. In addition, BTL has partnered with renowned, professional basketball player Andre Drummond to promote the BTL SCHOLAR DRAFT and award the winners. The program officially ki
- New International Recommendations for Treating Acne Scars with Energy-Based Deviceshttps://practicaldermatology.com/news/new-international-recommendations-for-treating-acne-scars-with-energy-based-devices/2460990/Energy-based devices are the first-line treatments for a variety of acne scars, according to new international consensus recommendations published in Lasers in Surgery and Medicine. For the first time
- Derms Give Back: Caring for Veteranshttps://practicaldermatology.com/news/derms-give-back-caring-for-veterans/2460989/Caring for veterans inspires dermatologists like Joshua E. Lane, MD every single day. Dr. Lane practices in Columbus, GA, near Fort Benning, a large military base, and many of his patients are veterans. He was so moved by their service and selflessness that he joined the
- Better Together: Castle Biosciences’ Full DecisionDx Portfolio to Be Interfaced with ModMed’s EMAhttps://practicaldermatology.com/news/better-together-castle-biosciences-full-decisiondx-portfolio-to-be-interfaced-with-modmeds-ema/2460982/Castle Biosciences, Inc’s full DecisionDx portfolio of dermatologic tests will be interfaces with EMA, ModMed’s electronic health records system, by year-end 2021 The interface is designed to enable dermatologic clinicians to order Castle’s De